Loading...
Loading...
Application 2025360500 · 00
| Application Number | 2025360500 |
| Registration Number | 1871041 |
| Status | 00 |
| Mark (native) | An image of a wild boar to the left of the word "DYNAMICURE". |
| Mark Type | madrid |
| Owner | DynamiCure Biotechnology, LLC |
| Filed | 2025-08-21 |
| Registered | 2025-03-10 |
An image of a wild boar to the left of the word "DYNAMICURE". has a current status of 00.
The specification below is taken directly from the filed record at the Japan Patent Office for each Nice class this trademark covers.
Pharmaceutical preparations and substances for the treatment of oncological diseases and disorders; pharmaceutical preparations for the treatment of oncological diseases and disorders; pharmaceutical preparations for the treatment of autoimmune diseases and disorders, autoimmune deficiency; pharmaceutical preparations for the treatment of genetic disorders; pharmaceutical preparations for the treatment of metabolic diseases; pharmaceutical preparations for the treatment of neurodegenerative diseases; pharmaceutical preparations for the treatment of kidney diseases; pharmaceutical preparations for the treatment of eye diseases; pharmaceutical preparations for the treatment of cardiovascular diseases; diagnostic biomarker reagents for medical purposes; protein arrays, namely, chemically prepared protein based diagnostic reagents for detecting disease biomarkers in biological samples for medical diagnosis purposes; diagnostic kits consisting primarily of monoclonal antibodies, buffers, and reagents for use in disease testing; diagnostic preparations for medical purposes; pharmaceutical preparations for the treatment of oncological diseases and disorders, autoimmune diseases and disorders, autoimmune deficiency, genetic disorders, metabolic diseases, neurodegenerative diseases, kidney diseases, eye diseases, cardiovascular diseases; all of the foregoing excluding treatments and diagnostics for neuromuscular disorders and orphan diseases.
Research and development services in the field of biologics, namely, antibodies and peptides for the treatment of cancer and immunotherapies; research and development in the pharmaceutical and biotechnology fields for the treatment of cancer and immunotherapies; providing medical and scientific research information in the field of pharmaceuticals and clinical trials in the field of cancer and immunotherapies; consulting services in the fields of biotechnology, pharmaceutical research and development, and pharmacogenetics in the field of cancer and immunotherapies; conducting research for others in the field of biotechnology, pharmaceutical research and development, laboratory testing, diagnostics, and pharmacogenetics in the field of cancer and immunotherapies; pharmaceutical research and development; research and development in the field of biologics, namely, antibodies and peptides for the field of cancer, immunotherapies, autoimmune diseases, autoimmune disorders, genetic disorders, metabolic diseases, neurodegenerative diseases, kidney diseases, eye diseases, and cardiovascular diseases; research and development in the field of pharmaceuticals, biopharmaceuticals, and biotechnologies for the treatment of cancer, immunotherapies, autoimmune diseases, autoimmune disorders, genetic disorders, metabolic diseases, neurodegenerative diseases, kidney diseases, eye diseases, and cardiovascular diseases; research and development in the field of biotechnology, pharmaceutical research and development, laboratory testing, diagnostics, and pharmacogenetics in the field of cancer, immunotherapies, autoimmune diseases, autoimmune disorders, genetic disorders, metabolic diseases, neurodegenerative diseases, kidney diseases eye diseases, and cardiovascular diseases; providing medical and scientific research information; consulting services in the field of pharmaceutical research and development; consulting services in the field of biotechnology; consulting services in the field of pharmacogenetics; research and development in the field of oncological diseases and disorders, autoimmune diseases and disorders, autoimmune deficiency, genetic disorders, metabolic diseases, neurodegenerative diseases, kidney diseases, eye diseases, cardiovascular diseases; all of the foregoing excluding treatments and diagnostics for neuromuscular disorders and orphan diseases.
| Name (romanised) | DynamiCure Biotechnology, LLC |
'An image of a wild boar to the left of the word "DYNAMICURE".' is a 00 trademark on the Japan Patent Office register, owned by DynamiCure Biotechnology, LLC. The application (2025360500) was filed on 21 August 2025 and registered on 10 March 2025.
This mark is recorded under multiple classes: Class 5 (pharmaceuticals & medical preparations); Class 42 (scientific, IT & design services), specifically covering: Pharmaceutical preparations and substances for the treatment of oncological diseases and disorders; pharmaceutical preparations for the treatment of oncological diseases and disorders; pharmaceutical preparations for the treatment of autoimmune diseases and disorders, autoimmune deficiency; pharmaceutical preparations for the treatment of genetic disorders; pharmaceutical preparations for the treatment of metabolic diseases; pharmaceutical preparations for the treatment of neurodegenerative diseases; pharmaceutical preparations for the treatment of kidney diseases; pharmaceutical preparations for the treatment of eye diseases; pharmaceutical preparations for the treatment of cardiovascular diseases; diagnostic biomarker reagents for medical purposes; protein arrays, namely, chemically prepared protein based diagnostic reagents for detecting disease biomarkers in biological samples for medical diagnosis purposes; diagnostic kits consisting primarily of monoclonal antibodies, buffers, and reagents for use in disease testing; diagnostic preparations for medical purposes; pharmaceutical preparations for the treatment of oncological diseases and disorders, autoimmune diseases and disorders, autoimmune deficiency, genetic disorders, metabolic diseases, neurodegenerative diseases, kidney diseases, eye diseases, cardiovascular diseases; all of the foregoing excluding treatments and diagnostics for neuromuscular disorders and orphan diseases.; Research and development services in the field of biologics, namely, antibodies and peptides for the treatment of cancer and immunotherapies; research and development in the pharmaceutical and biotechnology fields for the treatment of cancer and immunotherapies; providing medical and scientific research information in the field of pharmaceuticals and clinical trials in the field of cancer and immunotherapies; consulting services in the fields of biotechnology, pharmaceutical research and development, and pharmacogenetics in the field of cancer and immunotherapies; conducting research for others in the field of biotechnology, pharmaceutical research and development, laboratory testing, diagnostics, and pharmacogenetics in the field of cancer and immunotherapies; pharmaceutical research and development; research and development in the field of biologics, namely, antibodies and peptides for the field of cancer, immunotherapies, autoimmune diseases, autoimmune disorders, genetic disorders, metabolic diseases, neurodegenerative diseases, kidney diseases, eye diseases, and cardiovascular diseases; research and development in the field of pharmaceuticals, biopharmaceuticals, and biotechnologies for the treatment of cancer, immunotherapies, autoimmune diseases, autoimmune disorders, genetic disorders, metabolic diseases, neurodegenerative diseases, kidney diseases, eye diseases, and cardiovascular diseases; research and development in the field of biotechnology, pharmaceutical research and development, laboratory testing, diagnostics, and pharmacogenetics in the field of cancer, immunotherapies, autoimmune diseases, autoimmune disorders, genetic disorders, metabolic diseases, neurodegenerative diseases, kidney diseases eye diseases, and cardiovascular diseases; providing medical and scientific research information; consulting services in the field of pharmaceutical research and development; consulting services in the field of biotechnology; consulting services in the field of pharmacogenetics; research and development in the field of oncological diseases and disorders, autoimmune diseases and disorders, autoimmune deficiency, genetic disorders, metabolic diseases, neurodegenerative diseases, kidney diseases, eye diseases, cardiovascular diseases; all of the foregoing excluding treatments and diagnostics for neuromuscular disorders and orphan diseases.
Japanese trademark 2025360500 for the mark 'An image of a wild boar to the left of the word "DYNAMICURE".' in Class 5, 42 is recorded on the Japan Patent Office register as owned by DynamiCure Biotechnology, LLC. This covers one specific Japanese trademark record only — the same brand name may be owned by different parties in other classes, other countries, or as separate registrations.
No — the Japan Patent Office records the status of Japanese trademark 2025360500 for the mark 'An image of a wild boar to the left of the word "DYNAMICURE".' as 00.
Japanese trademark 2025360500 for the mark 'An image of a wild boar to the left of the word "DYNAMICURE".' is recorded in Class 5 (pharmaceuticals & medical preparations); Class 42 (scientific, IT & design services). The filed specification reads: Class 5: Pharmaceutical preparations and substances for the treatment of oncological diseases and disorders; pharmaceutical preparations for the treatment of oncological diseases and disorders; pharmaceutical preparations for the treatment of autoimmune diseases and disorders, autoimmune deficiency; pharmaceutical p…
Japanese trademark 2025360500 for the mark 'An image of a wild boar to the left of the word "DYNAMICURE".' was filed at the Japan Patent Office on 21 August 2025 and registered on 10 March 2025.
Japanese trademark data is supplied by the Japan Patent Office (JPO) via the JPO open bulk data release. Official government publications in Japan are not subject to copyright under Article 13 of the Japanese Copyright Act. Local copy last synchronised on 2026-04-25.
The “About This Trademark” summary and FAQ above are AI-generated from the register data shown on this page. They are factual summaries only — always verify details against the official register before making legal decisions.